However, anabolic side effects of anti-IL6 therapies are commonly reported in rheumatoid arthritis patients, including increased body weight and dyslipidaemia [171], suggesting that under steady state conditions IL6 is essential for a proper control of metabolic functions [153]. The gene discussed is IL6; the disease is inherited lipid metabolism disorder.